1. Two records with different authors
Registration is authored by the registrant. The firm submits its own name, address and business operations, and the FDA's acceptance of that submission carries no finding about the firm's manufacturing. An import alert is authored by the agency. Firms are placed on the Red List of Import Alert 66-40 when the FDA has information that an establishment is "not operating in conformity with current good manufacturing practice requirements". A certificate of analysis reports the first record and is silent on the second.
The distinction is familiar to regulatory staff and is easy to lose at the receiving dock, where the phrase "FDA registered" arrives printed on the supplier's own paper.
2. Registration: what the firm files
Part 207 of title 21 requires drug establishments to register and to keep the registration current. Section 207.29(b) sets the cycle. Registrants "must review and update all registration information" for each establishment, and those reviews "must occur annually, during the period beginning on October 1 and ending December 31 of each calendar year."
Section 207.77 states what the filing means. Paragraph (a) reads: "Registration of an establishment or listing of a drug does not denote approval of the establishment, the drug, or other drugs of the establishment, nor does it mean that a product may be legally marketed. Any representation that creates an impression of official approval or that a drug is approved or is legally marketable because of registration or listing is misleading and constitutes misbranding."
Paragraph (b) extends the point to the identifiers a buyer is most likely to be shown. The FDA's "assignment of an NDC does not denote approval of the establishment or the drug", and a representation that a drug is approved because "the establishment has been assigned an establishment registration number or Unique Facility Identifier is misleading and constitutes misbranding."
The public record of registration is the Drug Establishments Current Registration Site. Our FEI lookup guide walks through a search. A search by firm name returns the firm's name, its FDA Establishment Identifier, its DUNS number, its business operations and its address, and the page states the date through which its data are current.
3. Import Alert 66-40: what the FDA records
The alert's full name is "Detention Without Physical Examination of Drugs From Firms Which Have Not Met Drug GMPs". Its guidance tells FDA field staff that they "may detain, without physical examination, the indicated drugs or drug products from the foreign establishments on the Red List of this Import Alert."
The alert gives the basis for a listing. Detention without physical examination "may be appropriate when an FDA inspection, remote regulatory assessment, or inspection conducted by foreign or other government authorities under a Memorandum of Understanding or other agreement reveals that an establishment is not operating in conformity with CGMPs."
It also states how a listing ends. To remove a firm's product from the Red List, "information should be provided to the Agency to adequately demonstrate that the manufacturer has resolved the conditions that gave rise to the appearance of the violation." Detention "may apply until FDA has confidence that future shipments will not appear violative."
As published on November 12, 2026, the alert held about 470 firm entries. Forty-five of them carry a 2026 date, and sixteen of those are establishments in China. These figures are our count of the dated firm entries on the page and are approximate. A date on an entry may record an addition or a revision, so the 45 should not be read as 45 new listings.
4. One firm in both records
On November 18, 2026 we searched one API manufacturer in both places. The registration site returned a current record whose business operations include API manufacture. Import Alert 66-40 returned an entry for the same firm at the same street address, covering all of its drugs and drug products.
Nothing in either record is inconsistent with the other. The firm filed its registration, as part 207 requires of it. The FDA separately concluded that it had information warranting detention of the firm's drugs. A certificate from this manufacturer that says "FDA registered" states a fact.
We do not name the firm. The observation is offered as an instance, and we have not measured how many firms on the Red List hold a current registration.
5. Matching a firm across the two records
The two records are not keyed to each other on the page. An entry on the alert, as displayed, gives a firm name, an address, a date and product codes. The registration site gives a name, an establishment identifier and an address. In the instance above the two addresses shared a street, a street number and a city, and named the surrounding development zone in two different ways. The firm names differed in punctuation.
A name search alone is therefore unreliable in both directions. A small difference in spelling can hide a firm that is listed, and a common name can return a firm that is not the supplier. Our practice is to match on the street address and number, to record both spellings, and to keep a dated capture of each result.
6. What a negative result shows
A firm that does not appear on Import Alert 66-40 is a firm against which the FDA has not taken this action. The absence is not a finding that the firm operates under CGMP, and it says nothing about a particular lot. The alert is also one of several the FDA maintains for drugs, and this paper covers only 66-40.
The lookup has a direct use for pharmacies compounding under the HHS enforcement discretion policy for six peptides, announced October 30, 2026. Its fourth condition asks that the original manufacturer of the bulk drug substance "is registered with FDA under section 510, is in compliance with CGMP and other FD&C requirements". Registration answers the first clause. A listing on Import Alert 66-40 is public evidence that bears on the second.
7. The procedure
- Take the original manufacturer's name and address from the certificate of analysis. Where the lot came through a repackager or distributor, take theirs as well.
- Search the name on the Drug Establishments Current Registration Site. Record the establishment identifier, the business operations and the address, with the date the site gives for its data.
- Open Import Alert 66-40 and search the firm's name, then its street address. Record the published date of the alert.
- Where the firm appears, record the entry's date and the products it covers.
- File both captures with the supplier's qualification record, and repeat them at the interval your procedure sets.
8. Limits of this paper
Quotations are from the eCFR, current as of November 16, 2026, and from the FDA's pages as read on November 18, 2026. The counts in section 3 were made by a script on the alert as published November 12, 2026. Sections 5 and 7 describe our practice and are not requirements of the FDA.
Sources
- 21 CFR 207.29, "What are the requirements for reviewing and updating registration information?", paragraph (b).
- 21 CFR 207.77, "What legal status is conferred by registration and listing?", paragraphs (a) and (b).
- FDA, Import Alert 66-40, "Detention Without Physical Examination of Drugs From Firms Which Have Not Met Drug GMPs", published November 12, 2026.
- FDA, Drug Establishments Current Registration Site, data current through November 18, 2026.
- HHS, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances", announced at FR Doc. 2026-22192, October 30, 2026, condition 4.
A pharmacy or practice that wants its suppliers checked against both records, with the captures kept on file, can start with a free supplier check.
We review documents. We do not test material.